Immunome, Inc. (IMNM) vs Mineralys Therapeutics, Inc. (MLYS)

A side-by-side comparison of Immunome, Inc. and Mineralys Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Immunome, Inc. logo
IMNM
Immunome, Inc.
$1.93B
$20.23HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
Mineralys Therapeutics, Inc. logo
MLYS
Mineralys Therapeutics, Inc.
$1.99B
$22.55HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

Total return — IMNM vs MLYS

growth of $100 · dividends reinvested · last 4y
IMNM +298.7% (+41.3%/yr)MLYS +26.4% (+6.0%/yr)IMNM compounded faster over this window
0100200300400500Start $100202420252026$399$126
IMNM MLYS

IMNM vs MLYS: by the numbers

  • •MLYS is the larger company ($1.99B vs $1.93B market cap).
  • •Both run net losses; MLYS's is the smaller (0.00% vs -3059.99% net margin).

Metrics side by side

Valuation

MetricIMNMMLYS
P/B ratio3.683.61

Profitability

MetricIMNMMLYS
Gross margin57.43%0.00%
Operating margin-3084.76%0.00%
Net margin-3059.99%0.00%
ROE-48.43%-63.45%
ROIC-51.06%-57.17%

Growth (annualized)

MetricIMNMMLYS
Total return CAGR (5Y)2.88%N/A

Go deeper

Full IMNM analysisFull MLYS analysisInteractive comparison tool

Dig into the metrics

Immunome ROEMineralys Therapeutics ROEImmunome operating marginMineralys Therapeutics operating marginImmunome revenue growthMineralys Therapeutics revenue growthImmunome free cash flowMineralys Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.